Skip to main content
SpringerLink
Log in

Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal site

  • Review Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

At least half of all postmenopausal women will experience fractures during their lifetime, and the consequences are often serious, but most women at risk are not receiving adequate treatment. The objective of this paper is to summarize the literature concerning the consequences of osteoporotic fractures, and the effectiveness of pharmacologic agents for preventing fractures and their consequences, emphasizing a systematic, evidence-based summary of treatment results from randomized, controlled trials that were published previously. Osteoporosis is associated with increased risk of fractures at most skeletal sites. Hip fractures have much greater prognostic significance in terms of health than any other single type of fracture. However, symptomatic vertebral fractures and other non-hip fractures also represent enormous morbidity and economic burdens, and signal increased risk of future fractures of all types, including the hip. There is convincing evidence that two bisphosphonates (alendronate and risedronate) reduce the risk of both spine and non-spine fractures. The evidence for reducing hip fracture risk is greater for alendronate, with a consistent ∼50% reduction in hip fractures across studies. Alendronate has also been demonstrated to maintain quality of life by reducing outcomes such as hospitalization and bed rest related to back pain. Among other agents, raloxifene reduces the risk of vertebral fractures by approximately 30%; the published evidence for most other agents is inconclusive. Osteoporosis should be regarded as seriously as other important chronic disorders such as hypertension and hyperlipidemia. Postmenopausal patients with a high risk of fractures — such as those with prior fractures or osteoporosis as measured by BMD — need to be treated. Although other therapeutic modalities are available, the evidence is most convincing for the bisphosphonates, alendronate and risedronate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jones G., Nguyen T., Sambrook P.N., Kelly P.J., Gilbert C., Eisman J.A.: Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos. Int. 4: 277–282, 1994.

    Article  CAS  PubMed  Google Scholar 

  2. Cooper C.: The crippling consequences of fractures and their impact on quality of life. Am. J. Med. 103: 12S–19S, 1997.

    Article  CAS  PubMed  Google Scholar 

  3. Ross P.D.: Osteoporosis: Frequency, consequences, and risk factors. Arch. Intern. Med. 156: 1399–1411, 1996.

    Article  CAS  PubMed  Google Scholar 

  4. Torgerson D.J., Dolan P.: Prescribing by general practitioners after an osteoporotic fracture. Ann. Rheum. Dis. 57: 378–379, 1998.

    Article  CAS  PubMed  Google Scholar 

  5. Pal B.: Questionnaire survey of advice given to patients with fractures. BMJ 318: 500–501, 1999.

    Article  CAS  PubMed  Google Scholar 

  6. Morbidity and Mortality Weekly Report: Osteoporosis among estrogen-deficient women — United States, 1988–1994. MMWR 47: 969–973, 1998.

    Google Scholar 

  7. Consensus Development Conference: Prophylaxis and treatment of osteoporosis. Am. J. Med. 90: 107–110, 1991.

    Google Scholar 

  8. Hayes W.C., Myers E.R.: Biomechanics of fractures. In: Riggs B.L., Melton L.J. III (Eds.), Osteoporosis: Etiology, diagnosis, and management. Lippincott-Raven, Philadelphia, 1995, pp. 93–114.

    Google Scholar 

  9. Kanis J.A., Pitt F.A.: Epidemiology of osteoporosis. Bone 13: S7–S15, 1992.

    Article  PubMed  Google Scholar 

  10. Melton L.J. III: Epidemiology of age-related fractures. In: Avioli L. (Ed.), The Osteoporotic Syndrome. Detection, Prevention, and Treatment, ed. 3. Wiley-Liss, New York, 1993, pp. 17–38.

    Google Scholar 

  11. Seeley D.G., Browner W.S., Nevitt M.C., Genant H.K., Scott J.C., Cummings S.R.: Which fractures are associated with low appendicular bone mass in elderly women? Ann. Intern. Med. 115: 837–842, 1991.

    Article  CAS  PubMed  Google Scholar 

  12. Sanders K.M., Pasco J.A., Ugoni A.M., Nicholson G.C., Seeman E., Martin T.J., Skoric B., Panahi S., Kotowicz M.A.: The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: The Geelong Osteoporosis Study. J. Bone Miner. Res. 13: 1337–1342, 1998.

    Article  CAS  PubMed  Google Scholar 

  13. Lauritzen J.B., Schwarz P., Lund B., McNair P., Transbol I.: Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporos. Int. 3: 127–132, 1993.

    Article  CAS  PubMed  Google Scholar 

  14. Oden A., Dawson A., Dere W., Johnell O., Jonsson B., Kanis J.A.: Lifetime risk of hip fractures is underestimated. Osteoporos. Int. 8: 599–603, 1998.

    Article  CAS  PubMed  Google Scholar 

  15. Farmer M.E., White L.R., Brody J.A., Bailey K.R.: Race and sex differences in hip fracture incidence. Am. J. Public Health 74: 1374–1380, 1984.

    Article  CAS  PubMed  Google Scholar 

  16. Hagino H., Yamamoto K., Teshima R., Kishimoto H., Kuranobu K., Nakamura T.: The incidence of fractures of the proximal femur and the distal radius in Tottori Prefecture, Japan. Arch. Orthop. Trauma Surg. 109: 43–44, 1989.

    Article  Google Scholar 

  17. Johnell O., Gullberg B., Allander E., Kanis J.A., MEDOS Study Group: The apparent incidence of hip fracture in Europe: A study of national register sources. Osteoporos. Int. 2: 298–302, 1992.

    Article  CAS  PubMed  Google Scholar 

  18. Gullberg B., Johnell O., Kanis J.A.: World-wide projections for hip fracture. Osteoporos. Int. 7: 407–413, 1997.

    Article  CAS  PubMed  Google Scholar 

  19. Kanis J.A., Delmas P., Burckhardt P., Cooper C., Torgerson D., on behalf of the European Foundation for Osteoporosis and Bone Disease: Guidelines for diagnosis and management of osteoporosis. Osteoporos. Int. 7: 390–406, 1997.

    Article  CAS  PubMed  Google Scholar 

  20. US Congress, Office of Technology Assessment: Hip fracture outcomes in people aged fifty and over — Background paper, OTA-BP-H-120 Washington, DC: US Government Printing Office, July 1994.

    Google Scholar 

  21. Schurch M.A., Rizzoli R., Mermillod B., Vasey H., Michel J.P., Bonjour J.P.: A prospective study on socioeconomic aspects of fracture of the proximal femur. J. Bone Miner. Res. 11: 1935–1942, 1996.

    Article  CAS  PubMed  Google Scholar 

  22. Johnell O.: The socioeconomic burden of fractures: Today and in the 21st century. Am. J. Med. 103: 20S–26S, 1997.

    Article  CAS  PubMed  Google Scholar 

  23. Jalovaara P., Virkkunen H.: Quality of life after hemiarthroplasty for femoral neck fracture. Acta Orthop. Scand. 62: 208–217, 1991.

    Article  CAS  PubMed  Google Scholar 

  24. Cummings S.R., Black D.M., Rubin S.M.: Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch. Intern. Med. 149: 2445–2448, 1989.

    Article  CAS  PubMed  Google Scholar 

  25. Chrischilles E.A., Shireman T., Wallace R.: Costs and health effects of osteoporotic fractures. Bone 15: 377–386, 1994.

    Article  CAS  PubMed  Google Scholar 

  26. Phillips S., Fox N., Jacobs J., Wright W.E.: The direct medical costs of osteoporosis for American women aged 45 and older. Bone 9: 271–279, 1988.

    Article  CAS  PubMed  Google Scholar 

  27. Greendale G.A., Barrett-Connor E., Ingles S., Haile R.: Late physical activity and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study. J. Am. Geriatr. Soc. 43: 955–961, 1995.

    CAS  PubMed  Google Scholar 

  28. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., Eisman J.A.: Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 353: 878–882, 1999.

    Article  CAS  PubMed  Google Scholar 

  29. Cooper C., Atkinson E.J., Jacobsen S.J., O’Fallon W.M., Melton L.J. III: Population-based study of survival after osteoporotic fractures. Am. J. Epidemiol. 137: 1001–1005, 1993.

    CAS  PubMed  Google Scholar 

  30. Ross P.D.: Clinical consequences of vertebral fractures. Am. J. Med. 102 (Suppl. 6A): 30S–43S, 1997.

    Article  Google Scholar 

  31. Nevitt M.C., Ettinger B., Black D.M., Stone K., Jamal S.A., Ensrud K., Segal M., Genant H.K., Cummings S.R.: The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann. Intern. Med. 128: 793–800, 1998.

    Article  CAS  PubMed  Google Scholar 

  32. Huang C., Ross P.D., Wasnich R.D.: Vertebral fracture and other predictors of physical impairment and health care utilization. Arch. Intern. Med. 156: 2469–2475, 1996.

    Article  CAS  PubMed  Google Scholar 

  33. Nevitt M.C., Thompson D.E., Black D.M., Rubin S.R., Ensrud K., Yates A.J., Cummings S.R.: Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch. Intern. Med. 160: 77–85, 2000.

    Article  CAS  PubMed  Google Scholar 

  34. Ettinger B., Black D.M., Nevitt M.C., Rundle A.C., Cauley J.A., Cummings S.R., Genant H.K.: Contribution of vertebral deformities to chronic back pain and disability. J. Bone Miner. Res. 7: 449–456, 1994.

    Article  Google Scholar 

  35. Frost H.M.: Personal experience in managing acute compression fractures, their aftermath, and the bone pain syndrome, in osteoporosis. Osteoporos. Int. 8: 13–15, 1998.

    Article  CAS  PubMed  Google Scholar 

  36. Cook D.J., Guyatt G.H., Adachi J.D., Clifton J., Griffith L.E., Epstein R.S., Juniper E.F.: Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum. 36: 750–756, 1993.

    Article  CAS  PubMed  Google Scholar 

  37. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.S., Black D.: Risk of mortality following clinical fractures. Osteoporos. Int. 8 (Suppl. 3): 5, 1998 (Abstract).

    Google Scholar 

  38. Huang C., Ross P.D., Davis J.W., Wasnich R.D.: Contributions of vertebral fractures to stature loss among elderly Japanese-American women in Hawaii. J. Bone Miner. Res. 11: 408–411, 1996.

    Article  CAS  PubMed  Google Scholar 

  39. Leidig-Bruckner G., Minne H.W., Schlaich C., Wagner G., Scheidt-Nave C., Bruckner T., Gebest H.J., Ziegler R.: Clinical grading of spinal osteoporosis: Quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis. J. Bone Miner. Res. 12: 663–675, 1997.

    Article  CAS  PubMed  Google Scholar 

  40. Gold D.T.: The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18: 185S–189S, 1996.

    Article  CAS  PubMed  Google Scholar 

  41. Melton L.J. III: Hip fractures: A worldwide problem today and tomorrow. Bone 14 (Suppl.): S1–S8, 1993.

    Article  PubMed  Google Scholar 

  42. Ross P.D., Santora A., Yates A.J.: Epidemiology and consequences of osteoporotic fractures. In: Rosen C., Glowacki J., Bilezikian J.P. (Eds.), The Aging Skeleton. Academic Press, New York, 1999.

    Google Scholar 

  43. Doube A.: Managing osteoporosis in older people with fractures. BMJ 318: 477–478, 1999.

    Article  CAS  PubMed  Google Scholar 

  44. National Osteoporosis Foundation: Physician’s Guide to prevention and treatment of osteoporosis. Excerpta Medica, Belle Mead, New Jersey, 1998.

    Google Scholar 

  45. Schott A.M., Cormier C., Hans D., Favier F., Hausherr E., Dargent-Molina P., Delmas P.D., Ribot C., Sebert J.L., Breart G., Menuier P.J.: How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study. Osteoporos. Int. 8: 247–254, 1998.

    Article  CAS  PubMed  Google Scholar 

  46. Marshall D., Johnell O., Wedel H.: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 1254–1259, 1996.

    Article  CAS  PubMed  Google Scholar 

  47. Ross P.D., Genant H.K., Davis J.W., Miller P.D., Wasnich R.D.: Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos. Int. 3: 120–127, 1993.

    Article  CAS  PubMed  Google Scholar 

  48. Looker A.C., Wahner H.W., Dunn W.L., Calvo M.S., Harris T.B., Heyse S.P., Johnston C.C. Jr, Lindsay R.: Updated data on proximal femur bone mineral levels of US adults. Osteoporos. Int. 8: 468–489, 1998.

    Article  CAS  PubMed  Google Scholar 

  49. Klotzbuecher C., Ross P., Landsman P., Abbott T.A. III, Berger M.: Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J. Bone Miner. Res. 15: 721–739, 2000.

    Article  CAS  PubMed  Google Scholar 

  50. Black D.M., Arden N.K., Palermo L., Pearson J., Cummings S.R.: Prevalent vertebral deformities predict hip fractures and new vertebral deformities, but not wrist fractures. J. Bone Miner. Res. 14: 821–828, 1999.

    Article  CAS  PubMed  Google Scholar 

  51. Ross P.D., Davis J.W., Epstein R.S., Wasnich R.D.: Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann. Intern. Med. 114: 919–923, 1991.

    Article  CAS  PubMed  Google Scholar 

  52. Miller P.D., Siris E., Faulkner K.G., Abbott T., Furman D., Panish J., Barrett-Connor E., Berger M., Santora A., Sherwood L.: Use of the NOF guidelines with peripheral densitometry to predict fractures. Osteoporos. Int. 11 (Suppl. 2): S112, 2000 (Abstract).

    Google Scholar 

  53. Geusens P., Boonen S.: Risk assessment for osteoporosis using bone mineral density determination. J. Clin. Densitom. 1: 355–358, 1998.

    Article  CAS  PubMed  Google Scholar 

  54. Brennan N.J., Caplan G.A.: Attitudes to osteoporosis and hormone replacement therapy among elderly women. Osteoporos. Int. 9: 139–143, 1999.

    Article  CAS  PubMed  Google Scholar 

  55. Guyatt G.H.: Evidence-based management of patients with osteoporosis. J. Clin. Densitom. 1: 395–402, 1998.

    Article  CAS  PubMed  Google Scholar 

  56. Seeman E.: Osteoporosis: Trials and tribulations. Am. J. Med. 103 (Suppl. 2A): 74S–89S, 1997.

    Article  CAS  PubMed  Google Scholar 

  57. Meunier P.J.: Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials. Int. J. Clin. Pract. 53: 122–129, 1999.

    CAS  PubMed  Google Scholar 

  58. Hochberg M.C., Ross P.D., Black D., Cummings S.R., Genant H.K., Nevitt M.C., Barrett-Connor E., Musliner T., Thompson D.: Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum. 42: 1246–1254, 1999.

    Article  CAS  PubMed  Google Scholar 

  59. Riggs B.L., Hodgson S.F., O’Fallon W.M., Chao E.Y., Wahner H.W., Muhs J.M., Cedel S.L., Melton L.J. III: Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N. Engl. J. Med. 322: 802–809, 1990.

    Article  CAS  PubMed  Google Scholar 

  60. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535–1541, 1996.

    Article  CAS  PubMed  Google Scholar 

  61. Chapuy M.C., Arlot M.E., Delmas P.D., Meunier P.J.: Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308: 1081–1082, 1994.

    Article  CAS  PubMed  Google Scholar 

  62. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., Christiansen C., Delmas P.D., Zanchetta J.R., Stakkestad J., Gluer C.C., Krueger K., Cohen F.J., Eckert S., Ensrud K.E., Avioli L.V., Lips P., Cummings S.R.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282: 637–645, 1999.

    Article  CAS  PubMed  Google Scholar 

  63. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., Chesnut C.H. III, Brown J., Eriksen E.F., Hoseyni M.S., Axelrod D.W., Miller P.D.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352, 1999.

    Article  CAS  PubMed  Google Scholar 

  64. Reginster J.Y., Minne H.W., Sorensen O.H.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 11: 83–91, 2000.

    Article  CAS  PubMed  Google Scholar 

  65. U.S. Food and Drug Administration: Product package insert for risedronate, 2000.

    Google Scholar 

  66. Miller P., Roux C., McClung M.: Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. Arthritis Rheum. 42 (Suppl. 9): S287, 1999.

    Google Scholar 

  67. Hochberg M.C.: Preventing fractures in postmenopausal women with osteoporosis: A review of recent controlled trials of antiresorptive agents. Drugs Aging 2000 (in press).

    Google Scholar 

  68. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Palermo L., Prineas R., Rubin S.M., Scott J.C., Vogt T., Wallace R., Yates A.J., LaCroix A.Z.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. JAMA 280: 2077–2082, 1998.

    Article  CAS  PubMed  Google Scholar 

  69. Liberman U.A., Weiss S.R., Bröll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C. II, Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333: 1437–1443, 1995.

    Article  CAS  PubMed  Google Scholar 

  70. Karpf D.B., Shapiro D.R., Seeman E., Ensrud K.E., Johnston C.C. Jr, Adami S., Harris S.T., Santora A.C. II, Hirsch L.J., Oppenheimer L., Thompson D.: Prevention of nonvertebral fractures by alendronate: a meta-analysis. JAMA 277: 1159–1164, 1997.

    Article  CAS  PubMed  Google Scholar 

  71. Ensrud K., Thompson D., Nevitt M., Hochberg M., Santora A., Black D.M.: Prevalent vertebral fractures predict hospitalization and mortality in older women: The Fracture Intervention Trial (FIT). Osteoporos. Int. 8: 28, 1998 (Abstract).

    Google Scholar 

  72. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P., Roux C., Pinchera A., Foldes A.J., Greenspan S.L., Levine M.A., Emkey R., Santora A.C. II, Kaur A., Thompson D.E., Yates J., Orloff J.J., for the Alendronate Once-Weekly Study Group.: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin. Exp. Res. 12: 1–12, 2000.

    Article  CAS  Google Scholar 

  73. Lips P., Graafmans W.C., Ooms M.E., Bezemer P.D., Bouter L.M.: Vitamin D supplementation and fracture incidence in elderly persons. Ann. Intern. Med. 124: 400–406, 1996.

    Article  CAS  PubMed  Google Scholar 

  74. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E.: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337: 670–676, 1997.

    Article  CAS  PubMed  Google Scholar 

  75. Riggs B.L., O’Fallon W.M., Muhs J., O’Connor M.K., Kumar R., Melton L.J. III: Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J. Bone Miner. Res. 13: 168–174, 1998.

    Article  CAS  PubMed  Google Scholar 

  76. Cosman F., Cummings S., Lindsay R.: How long should patients with osteoporosis be treated with bisphosphonates? J. Women’s Health Gender-based Med. 9: 81–84, 2000.

    Article  CAS  Google Scholar 

  77. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C-J., Wasnich R.D., Bone H.G., Santora A.C., Wu M., Desai R., Ross P.D.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J. Clin. Endocrinol. Metab. 85: 3109–3115, 2000.

    CAS  PubMed  Google Scholar 

  78. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C. Jr, Burr D.B.: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15: 613–620, 2000.

    Article  CAS  PubMed  Google Scholar 

  79. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., Opas E.E., Seedor J.G., Klein H., Frankenfield D.: The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92: 2577–2586, 1993.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  80. Weinstein R.S.: True strength. J. Bone Miner. Res. 15: 621–625, 2000.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MCP-Hahnemann University School of Medicine, Philadelphia, Pennsylvania, USA

    S. Epstein M.D.

Authors
  1. S. Epstein M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Epstein M.D..

Additional information

Address where work was conducted.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Epstein, S. Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal site. Aging Clin Exp Res 12, 330–341 (2000). https://doi.org/10.1007/BF03339858

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03339858

Key words

Search

Navigation